BrainsWay (BWAY) Q2 2026: 42% System Shipment Growth Fuels Platform Expansion and Revenue Visibility
BrainsWay accelerated its transition from a pure Deep TMS system provider to a broader interventional psychiatry platform, driven by record system shipments and expanding recurring revenue streams. The company’s growing installed base, rising remaining performance obligations, and expanding reimbursement coverage underpin a raised full-year guidance. Strategic minority investments and international expansion initiatives reinforce its long-term growth trajectory.
Summary
- Platform Evolution Momentum: BrainsWay is evolving beyond Deep TMS hardware into a comprehensive interventional psychiatry services platform.
- Revenue Visibility Expansion: A 30% increase in remaining performance obligations signals strong future revenue visibility and recurring revenue potential.
- Strategic Growth Investments: Minority investments and international market expansion position the company for sustained long-term growth.
Business Overview
BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments, primarily through its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The company generates revenue by selling and leasing Deep TMS systems, delivering treatment protocols, and expanding clinical indications. Its business model focuses on hardware sales, recurring revenues from system utilization, and expanding reimbursement coverage. Major segments include system shipments, clinical protocol development, and strategic minority investments in behavioral health platforms.
Performance Analysis
In Q2 2026, BrainsWay reported a 35% year-over-year revenue increase to $17.1 million, driven by a record shipment of 125 Deep TMS systems, representing a 42% increase compared to the prior year. The installed base approached 1,950 systems, a critical mass that supports recurring revenue through increased utilization and multi-year service agreements. Gross margin remained robust and stable at 75%, reflecting operational efficiency despite increased scale. Operating income surged over 300% to $2.4 million, with operating margin expanding significantly from 5% to 14%, signaling effective cost control and operating leverage.
Adjusted EBITDA more than doubled to $3.5 million, with margin expansion from 11% to 20%. This profitability improvement was achieved alongside steady sales and marketing expenses, highlighting improved efficiency in the commercial organization. Remaining performance obligations (RPO), a key metric representing contracted future revenue, grew 30% to $80.4 million, underscoring strong demand and revenue visibility. The company generated $6.3 million in operating cash flow, reinforcing financial strength and flexibility. These financial dynamics reflect a scalable business model transitioning from upfront hardware sales toward a platform with growing recurring revenue streams.
- Shipment Growth as Revenue Driver: Record 125 systems shipped, fueling installed base expansion and recurring revenue potential.
- Margin Expansion Through Operating Leverage: Operating margin tripled, driven by disciplined cost management and sales efficiency.
- Revenue Visibility Strengthened: RPO growth of 30% enhances forward-looking revenue certainty.
The quarter’s results demonstrate BrainsWay’s ability to balance growth with profitability while building a foundation for long-term platform expansion beyond its legacy Deep TMS hardware business.
Executive Commentary
"We entered the second half of 2026 from a position of strength, with accelerating growth, expanding profitability, and increasing visibility into future revenue. Every system we install, every reimbursement expansion we achieve, and every new clinical indication we develop strengthen the platform and expand our long-term opportunities."
Hadar Levy, Chief Executive Officer
"Gross margin remained stable at 75% while we increased shipments and expanded our installed base. Our operating income increased more than 300%, reflecting the scalable nature of our business model and disciplined cost control."
Ido Marom, Chief Financial Officer
Strategic Positioning
1. Transition to a Broader Interventional Psychiatry Platform
BrainsWay is evolving from a Deep TMS system provider into a comprehensive platform offering interventional psychiatry services. This includes expanding clinical indications such as comorbid PTSD and major depressive disorder, supported by FDA submissions and new clinical data. The company’s strategy leverages each installed system to generate multi-year recurring revenue through additional protocols and utilization, underpinning a scalable growth model.
2. Expansion of Reimbursement Coverage and Utilization
The company has extended insurance coverage for its SWIFT accelerated Deep TMS protocols to approximately 57 million covered lives in the U.S., driving broader patient access. This reimbursement expansion fuels increased utilization within the installed base, enhancing recurring revenue and improving the value proposition for healthcare providers.
3. Strategic Minority Investment Program
BrainsWay’s investment in behavioral health platforms like Hopemark Health exemplifies its approach to growing patient access and provider networks. These minority stakes not only provide financial returns but also deepen BrainsWay’s integration within the broader behavioral health ecosystem, accelerating adoption and utilization of its technologies.
4. International Market Expansion
With an estimated 170 million untreated patients in current partner markets, BrainsWay is leveraging existing commercial partnerships to scale internationally. This capital-efficient expansion strategy aims to capture growth in global interventional psychiatry demand, diversifying revenue sources beyond the U.S. market.
5. Future Home-Based Neuromodulation Opportunities
The company is exploring extending neuromodulation treatments beyond clinical settings into home use, supported by investments in companies like Novalif. This initiative aligns with the broader trend toward digital health and remote patient monitoring, potentially unlocking new growth avenues and enhancing patient engagement.
Key Considerations
BrainsWay’s Q2 results highlight a pivotal phase in its strategic evolution, balancing robust near-term growth with investments in future platform capabilities.
- Installed Base Leverage: Growth in system shipments and installed units is critical to expanding recurring revenue and clinical data accumulation.
- Reimbursement as Growth Catalyst: Continued expansion of insurance coverage is essential to driving utilization and market penetration.
- Capital Allocation Discipline: Minority investments are selective, targeting scalable behavioral health platforms to maximize strategic and financial returns.
- Operational Efficiency: Stable sales and marketing spend amid revenue growth indicates effective cost management supporting margin expansion.
- Regulatory and Clinical Validation: Ongoing FDA submissions and clinical data releases underpin expansion into new treatment indications, broadening the addressable market.
Risks
Key risks include potential delays in regulatory approvals for new clinical indications, reimbursement uncertainties, and execution risks associated with scaling minority investments and international expansion. Competitive pressures in the neuromodulation market and dependence on continued adoption by healthcare providers also present challenges to sustained growth.
Forward Outlook
For Q3 2026, BrainsWay expects continued momentum, supported by growing RPO and system demand. For full-year 2026, management raised revenue guidance to $68 million to $70 million, reflecting 30% to 34% growth year-over-year. Operating income margin is projected between 13.5% and 14%, and adjusted EBITDA is expected to reach $13 million to $14 million, nearly doubling from 2025. Management emphasized strong visibility into the second half of the year driven by backlog growth and expanding reimbursement coverage.
Takeaways
BrainsWay’s Q2 2026 results affirm its successful execution on a multi-dimensional growth strategy that blends hardware sales with platform expansion and recurring revenue enhancement.
- Scalable Growth Model: The 42% increase in system shipments and 30% growth in remaining performance obligations highlight a scalable model with growing revenue visibility and profitability.
- Strategic Ecosystem Integration: Minority investments and clinical pipeline advances deepen BrainsWay’s footprint in behavioral health, positioning it to capitalize on interventional psychiatry’s growth.
- Forward-Looking Indicators: Rising installed base, reimbursement expansion, and international initiatives are key metrics to monitor for sustained growth and margin expansion.
Conclusion
BrainsWay’s second quarter results demonstrate robust growth, margin expansion, and strategic progress toward becoming a leading interventional psychiatry platform. The company’s elevated revenue guidance and expanding backlog underscore strong demand and operational execution, setting a foundation for long-term value creation.
Industry Read-Through
BrainsWay’s performance and strategic initiatives reflect broader trends in the neurostimulation and behavioral health sectors, including the shift toward platform-based care models and integration of digital health solutions. The company’s success in expanding reimbursement coverage and leveraging minority investments may serve as a blueprint for peers seeking to scale interventional psychiatry offerings. Additionally, the focus on home-based neuromodulation underscores industry movement toward patient-centric, remote treatment modalities, signaling potential disruption in traditional clinic-centric care delivery.